Skip to main content

Table 1 Comparison of baseline characteristics of participants

From: Prevalence, characteristics, and risk of exacerbation in young patients with chronic obstructive pulmonary disease

 

Non-COPD (n = 2141)

Young COPD (n = 95)

p value

Never-smoker

Ever-smoker

Never-smoker

Ever-smoker

Subjects (N)

1294

847

36

59

 

Age, years

44.47 ± 5

44.37 ± 5

45.06 ± 6

44.98 ± 4

0.255

Sex, male (%)

163 (12.6)

761 (89.9)

7 (19.4)

55 (93.2)

< 0.001

BMI (kg/m2)

23.87 ± 3.98

24.65 ± 3.83

23.54 ± 4.58

23.74 ± 3.90

< 0.001

Smoking, pack-year

0

18.77 ± 15.65

0

22.52 ± 15.00

< 0.001

Comorbid condition

 DM

121 (9.4)

99 (11.7)

5 (13.9)

7 (11.9)

0.302

 HTN

194 (15.0)

162 (19.1)

4 (11.1)

12 (20.3)

0.053

Ischemic heart disease

16 (1.24)

18 (2.13)

1 (2.78)

3 (5.1)

0.076

Congestive heart failure

9 (0.7)

4 (0.5)

0

1 (1.7)

0.630)

 Gastroesophageal reflux disease

473 (36.6)

247 (29.2)

14 (38.9)

20 (33.9)

0.005

 History of PTB

8 (0.6)

8 (0.94)

2 (5.6)

1 (1.7)

0.012

 Depression

76 (5.9)

28 (3.3)

2 (5.6)

7 (11.9)

0.005

 Atopic dermatitis

57 (4.4)

27 (3.2)

3 (8.3)

3 (5.1)

0.270

 Any allergya

521 (40.3)

295 (34.8)

15 (41.7)

18 (30.5)

0.045

 Asthma

214 (16.5)

96 (11.3)

11 (30.6)

7 (11.9)

< 0.001

Index of quality of life, EQ-5D

0.97 ± 0.09

0.97 ± 0

0.95 ± 0.09

0.96 ± 0.09

0.224

Lung function

 FEV1, % predicted

93.79 ± 14.25

92.37 ± 13.42

72.91 ± 15.05

75.00 ± 14.81

 < 0.001

 FVC, % predicted

94.51 ± 14.32

93.38 ± 14.19

93.40 ± 15.42

94.27 ± 16.69

0.139

 FEV1/FVC, %

0.83 ± 0.06

0.81 ± 0.07

0.65 ± 0.06

0.65 ± 0.05

 < 0.001

  1. Data are presented as number (%) or mean ± inter-quartile range
  2. BMI, body mass index; DM, diabetes mellitus; GERD, gastroesophageal reflux disease; EQ-5D, EuroQol-5 dimensions questionnaire; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HTN, hypertension; ICS, inhaled corticosteroid; LABA, long-acting beta2 receptor agonist; LAMA, long-acting muscarinic receptor agonist; PTB, pulmonary tuberculosis; SABA, short-acting beta2 receptor agonist; SAMA, short-acting muscarinic receptor agonist
  3. aHistory of allergic dermatitis/urticarial, contact dermatitis, food or drug allergy and allergic reaction were included